Konatham Teja Kumar Reddy has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Alapati Sahithi Reddy

    Department of Pharmaceutical Analysis, Nalla Narasimha Reddy Education Society, Group of Institutions, Via Narapally, Ghatkesar Mandal, Korremula Rd, Hyderabad, Telangana 500088, India

    2 shared publications
  • M. Akiful Haque

    Associate Professor, Department of Pharmaceutical Analysis, Anurag University Venkatapur Ghatkesar Rd, Hyderabad Telangana-500088

    2 shared publications
  • Adel Ehab Ibrahim

    Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, Nizwa 616, Oman

    1 shared publication
  • Alapati Sahithi

    Department of Pharmaceutical Analysis, Nalla Narasimha Reddy Education Society’s Group of Institutions, Hyderabad, India

    1 shared publication
  • Anil Kumar Tallam

    Department of Pharmacy, Shri Venkateshwara University, Rajabpur, India

    1 shared publication
  • Anoop Bodapati

    Department of Pharmaceutical Sciences Vignan's Foundation for Science, Technology & Research (Deemed to be University), Guntur-Tenali Rd, Vadlamudi, Andhra Pradesh-522213, India

    1 shared publication

Latest Publications

  • Open Access

    Recent breakthroughs in drug delivery systems for targeted cancer therapy: an overview

    by Konatham Teja Kumar Reddy, Alapati Sahithi Reddy

    Targeted drug delivery systems have emerged as promising approaches for improving the efficacy and safety of cancer therapy. This review highlights recent advancements in drug delivery technologies aimed at achieving targeted and personalized treatment strategies for cancer patients. The integration of nanotechnology, biomaterials, and molecular targeting strategies has enabled the development of sophisticated drug delivery systems capable of selectively delivering therapeutic agents to tumour tissues while minimizing off-target effects on healthy tissues. Various targeting mechanisms, including passive and active targeting strategies, exploit the unique physiological characteristics of tumours, such as abnormal vasculature, overexpressed receptors, and altered microenvironments, to achieve selective accumulation and retention of drugs within tumour tissues. Nanoparticle-based drug delivery systems, such as liposomes, polymeric nanoparticles, and inorganic nanoparticles, offer advantages in terms of drug loading capacity, sustained release, and tumour targeting, making them attractive platforms for targeted cancer therapy. Moreover, the integration of smart drug delivery systems that respond to specific stimuli within the tumor microenvironment, such as pH, temperature, or enzyme activity, holds promise for enhancing tumor specificity and reducing systemic toxicity. Combination therapy approaches, which combine targeted drug delivery with other therapeutic modalities, such as immunotherapy or photodynamic therapy, offer synergistic effects and opportunities for overcoming treatment resistance. Despite these advancements, several challenges remain, including the translation of preclinical research findings into clinically viable therapies, regulatory approval, manufacturing scalability, and biomarker discovery. Addressing these challenges and embracing innovative approaches will be essential for realizing the full potential of targeted drug delivery systems in improving patient outcomes and advancing cancer therapy.


  • Open Access

    Bioanalytical method development for monoclonal antibodies: advances and challenges

    by Sudha Divya Madhuri Kallam, Anoop Bodapati, Alapati Sahithi Reddy, Konatham Teja Kumar Reddy

    Monoclonal antibodies (mAbs) represent a cornerstone of modern therapeutic strategies, targeting a wide array of diseases with unprecedented specificity. Developing and validating bioanalytical methods for mAbs are critical to ensuring their efficacy, safety, and regulatory compliance. This review discusses the recent advances in bioanalytical technologies and the persistent challenges faced in the field. Significant progress has been made in chromatographic techniques, mass spectrometry, and capillary electrophoresis, enhancing the analysis of mAbs in terms of resolution, sensitivity, and throughput. Innovations such as high-resolution mass spectrometry and automated capillary electrophoresis systems have transformed the mAb characterization landscape. However, challenges remain, primarily due to the complex nature of mAbs, which necessitates the development of susceptible and specific methods to determine their pharmacokinetic profiles and detect low-abundance impurities accurately. Moreover, the stringent and evolving regulatory requirements demand robust and reproducible analytical methods. This review emphasizes the need for continuous technological innovation and adaptation to address these challenges effectively.


  • Bioanalytical Method Development and Validation for the Estimation of Hydroxyproline in Urine Samples of Osteoarthritic Patients Using LC–MS/MS Technique

    by Anil Kumar Tallam, Konatham Teja Kumar Reddy, Uttam Prasad Panigrahy, Alapati Sahithi, S. Prema, Jeetendra Kumar Gupta, D. Jeslin, Aparajita Neogi, Vinod Thomas, R. S. Chandan


  • Open Access

    LC-MS/MS Bioanalytical Procedure for Atrasentan in Human Plasma: Method Development and Validation

    by Konatham Tk Reddy, M Akiful Haque

    11ABSTRACTObjectives: The objective of this work is to establish a bioanalytical technique for the quantification of atrasentan. The employed methodology for the detection and quantification of atrasentan in human plasma has a high degree of specificity, sensitivity, and simplicity. Methods: Shimadzu pumps were utilized in conjunction with an Autosampler Agilent Zorbax XDB C18 2.1 × 50 mm, 5 μm column employed as a stationary phase to achieve the chromatographic separation. Acetonitrile (0.1% formic acid) and 5 mM ammonium formate made up the mobile phase, which was optimized to have a 70:30% v/v ratio. Isocratic elution was employed in the experiment, with a flow rate of 0.150 mL/min. The entire cycle took 3.0 minutes, using a 10 μL injection volume. Results: The detection procedure is executed utilizing positive ion mode electrospray ionization (ESI) mass spectrometry under atmospheric pressure. For atrasentan, the precursor to product ion transitions used for quantification was m/z 511.623 to 354.15 and for the internal standard, verapamil, m/z 455.22 to 165. 02. The retention times for atrasentan and verapamil were found to be 1.68 and 0.96 minutes, respectively.Conclusion: In accordance with the recommendations of the United States Food and Drug Administration (USFDA) and EMA, it was ascertained that the remaining validation parameters remained within the specified range.

  • Open Access

    Determination of Sodium, Potassium, and Magnesium as Sulfate Salts in Oral Preparations Using Ion Chromatography and Conductivity Detection

    by Suresh Reddy Yelampalli, Kumaraswamy Gandla, Konatham Teja Kumar Reddy, Adel Ehab Ibrahim, Sami El Deeb

    An ion chromatography technique with conductivity detection was selected as an analytical tool for the simultaneous indirect determination of sodium sulfate, potassium sulfate, and magnesium sulfate via their respective cations. The method was developed and validated for the quantitative assay of the inorganic salts under study in oral pharmaceutical dosage forms. Chromatographic separation was achieved on a Dionex®IonPac® CS16 column (250 × 5 mm) column using the gradient elution method. A mobile phase-A consisting of methane sulfonic acid (6.7%, v/v) in Milli-Q water, which is used together with Milli-Q water, was used as a mobile Phase-B. The flow rate was 1.2 mL/min. The retention times of sodium, potassium, and magnesium as sulfates were 7.8, 12.8, and 16.2 min, respectively. The method was validated according to ICH guidelines and showed good linearity and accuracy results within concentration ranges of 80.0–240.0, 20.0–60.0, and 4.5–13.5 ppm for sodium, potassium, and magnesium as sulfates, respectively. The relative standard deviation results for intra- and inter-day precision were less than 1.0%. The method was applied successfully for determination of the analytes under study in their mixed pharmaceutical oral solution and found suitable for their routine and stability analysis.


  • Open Access

    Eradication of spurious adulterated and under standard quality drugs, a regulatory pertaining in Indian regulatory system

    by S Rajesh, Jothieswari Dhamotharan, P. Suresh Kumar, M. Arockia Babu, M Jagadeesan, Konatham Teja Kumar Reddy

    Drugs and pharmaceuticals have become an integral part of the lives of human beings as well as animals. They play an important role in saving lives, restoring health, preventing ailments, avoiding epidemics, and maintaining general well-being. In order to achieve this objective, they are required to be safe, efficacious, and of desired quality. As a deterrent and challenge in achieving this objective, the menace of Spurious, Adulterated, and Not of Standard Quality drugs have emerged as the biggest hurdles globally. Though Spurious and Adulterated drugs have attracted concerns of the society and Government agencies, the issue of Not of Standard Quality drugs has not been addressed satisfactorily. If a drug is not of desired quality, it shall not deliver the required benefits to the patient and thereby fails to achieve the basic objective of consuming the drug leading to dire consequences or even death.

  • Open Access

    Bioanalytical method development and validation of atrasentan in human plasma using verapamil as internal standard by liquid chromatography coupled with tandem mass spectrometry

    by Konatham Teja Kumar Reddy, M. Akiful Haque

    A satisfactory LC-MS/MS separation and good peak symmetry for Atrasentan were obtained with Agilent, Zorbax, XDB C18 (2.1 x 50 mm ID, 5 μm), and a mobile phase containing a mixture of 5 mM Ammonium Formate buffer with 0.1% formic acid were mixed with HPLC grade Acetonitrile in the proportion of 70:30, v/v was delivered at a flow rate of 0.150 mL/min by positive ion mode (API 4000) with an injection volume of 10 µL and a run time of 3 min. Detection is performed by atmospheric pressure electrospray ionization (ESI) mass spectrometry in positive ion mode. The precursor to product ion transitions is m/z 5.11.600 to 354.04 for Atrasentan, and m/z 455.40 to 165.00 for Verapamil (Internal standard) were used for quantization. The retention time of Atrasentan and Verapamil (Internal standard) was found to be 1.68 & 0.96 min.


  • Open Access

    Bioanalytical method development and validation of atrasentan in human plasma using verapamil as internal standard by liquid chromatography coupled with tandem mass spectrometry

    by Konatham Teja Kumar Reddy, M. Akiful Haque

    A satisfactory LC-MS/MS separation and good peak symmetry for Atrasentan were obtained with Agilent, Zorbax, XDB C18 (2.1 x 50 mm ID, 5 μm), and a mobile phase containing a mixture of 5 mM Ammonium Formate buffer with 0.1% formic acid were mixed with HPLC grade Acetonitrile in the proportion of 70:30, v/v was delivered at a flow rate of 0.150 mL/min by positive ion mode (API 4000) with an injection volume of 10 µL and a run time of 3 min. Detection is performed by atmospheric pressure electrospray ionization (ESI) mass spectrometry in positive ion mode. The precursor to product ion transitions is m/z 5.11.600 to 354.04 for Atrasentan, and m/z 455.40 to 165.00 for Verapamil (Internal standard) were used for quantization. The retention time of Atrasentan and Verapamil (Internal standard) was found to be 1.68 & 0.96 min.